Neuravi has announced €15 million in venture debt financing from IPF Partners, a leading alternative financing provider focused on the healthcare sector.
This financing allows Neuravi to invest in US commercialisation and stroke treatment portfolio expansion, building upon successful commercialization of the company’s EmboTrap Revascularization Device in Europe and rapid progress enrolling the ARISE II US pivotal study.
Landmark acute stroke clinical trials published in 2014 and 2015 demonstrating the superiority of stent retriever technology in treating large vessel strokes have driven a surge in the number of stent retriever procedures. Based on extensive physician engagement and Neuravi’s work on the science of clot, Neuravi has built a strong pipeline of products focused exclusively on acute ischaemic stroke and intends to commercialise this pipeline globally in the years ahead, the company reports in a press release.
“With the recent European launch of the EmboTrap II device and the excellent progress in enrolling our pivotal clinical trial, we are making significant headway in delivering next-generation technology for stroke treatment to physicians. This financing allows us to build our commercial presence in the USA and further invest in R&D for our exciting product pipeline,” said Eamon Brady, Neuravi CEO. “We see significant innovation opportunity due to the under-developed stroke treatment ‘toolbox’ available to stroke clinicians today. Our vision is to design and build devices that truly address the needs of acute stroke patients and put them in the hands of stroke physicians all over the world. This funding is an important step on our roadmap.”